Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good luck if you're still in.
This company is now on my "pump-n-dump" list.
The company diluted this back to $8 dollars.
yep…$$$ long long
Shorts closed out - longs taking over?
* * $BXRX Video Chart 02-21-2020 * *
Link to Video - click here to watch the technical chart video
Great buying opp at this extreme low price ..Market cap of $86 million is a bog joke for a biotech with an approved drug which has $350 million potential
Shorts have their quota for the day. They'll raise the price now going into the close.
Looks like this CC happened on Feb 20. The presentation is already on the company website.
Today at 430est. See crudeoil's post. .or company website for details
Is there a conference call? If so, what day/time?
Thanks in advance.
Reloded !! Lets go
Next is CTDH with imminent resoults of their Niemann-Pick Diesease a $500 Million Market with NO approved Drug to date
CTDH= Price 0.18 --MC $23 M --Clinical results from NPC trial imminent (during this Q) ,positive results could boost this unknown stock to $1 or more in no time .They have also an attractive Alzheimer programm ongoing . Dirt cheap stock with BRUTAL upside potential .GLTA
Wow. I didn't expect the company to hit the bid so hard.
But I guess the company needs money.
If and when the company stops selling -- this should run.
Otherwise...this is stuck around $8.00
Congrats $$$ enjoy your day crude find anything today shoot me a pm thanks ;)
Last 11.17. Volume 258,984.
What last trade are you showing?
I'm not showing any trades in the last 10 minutes,tried buying at the ask just now and nothing.
Sold all my position @ 11.20 & higher , > Beautiful ATM!
Out @$11.50 gotta secure the bag as dj khaled would say easy$
Goodluck traders !
$11.50 ish at 7 a.m. Picking up steam.
10.50 premarket gapping :D
Conference Call and Webcast:
Baudax Bio management will be hosting a conference call and webcast today beginning at 4:30 p.m. ET. To access the conference call, please dial (866) 220-5595 (local) or (615) 622-8062 (international) at least 10 minutes prior to the start time and refer to conference ID 4373423.A live audio webcast of the call will be available under "Events" in the Investor section of the Company's website, https://www.baudaxbio.com/news-and-investors/events. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.
know trading in uncharted territory company record high !
Agree! > We traded over 1 million shares in AH. > And that includes several Nasdaq circuit breaker halts in AH.
Tutes > mutual funds, pension funds, endowment funds, and hedge funds will be adding to their BXRX positions tomorrow, and next week.
Nice! TY for the correction. Tomorrow is looking good.
It is only 3 million shares @ $ 8.30 a share. > that will be absorbed in 30 minutes of trading. I expect volume to run well past 15 million tomorrow morning > No big deal!
Common stock offered by us Shares of our common stock having an aggregate offering price of up to $25,000,000.Manner of Offering “At the market offerings” that may be made from time to time through our sales agent, JMP. See “Plan of Distribution” on page S-16 of this prospectus supplement.
Common stock to be outstanding
immediately after this offering
12,362,757 shares, assuming sales at a price of $8.30 per share, which was the last reported sale price of our common stock on February 12, 2020.Use of proceeds We currently intend to use the net proceeds from this offering for preparatory commercial activities for the potential commercial launch of IV meloxicam, pipeline development activities, and general corporate purposes. See “Use of Proceeds.”Risk Factors An investment in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-5 of this prospectus supplement and page 7 of the accompanying prospectus and the similarly titled sections in the documents incorporated by reference into this prospectus supplement.The Nasdaq Capital Market symbol BXRX
The number of shares of our common stock to be outstanding immediately after this offering is based on 9,350,709 shares of our common stock outstanding as of December 31, 2019, and excludes:
•
643,879 shares of our common stock issuable upon the exercise of stock options outstanding as of December 31, 2019 at a weighted- average exercise price of $6.33 per share;
•
1,380,030 shares of our common stock issuable upon the vesting and settlement of restricted stock units outstanding as of December 31, 2019; and
•
1,443,626 shares of our common stock available for future issuance as of December 31, 2019 under our 2019 Equity Incentive Plan.
Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ANJESO™ (meloxicam injection), which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
“The approval of ANJESO marks a major advancement in the treatment landscape for managing moderate to severe pain,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. “With our nation currently in the midst of a national opioid epidemic, we are thrilled to be able to offer a novel, non-opioid therapeutic option with the potential to meaningfully impact the acute pain treatment paradigm. We expect to make ANJESO available to physicians and patients in late April or early May 2020.”
They have a 25 million offering they filed last December, at the market offering
9.7% short / 8 Mill Float / All time
High uncharted territory = $$$$
https://stockcharts.com/h-sc/ui?s=bxrx
The float is so low, we may see 24.00+ tomorrow!
This should run big tomorrow $$$
Only up 29% ? Tons of room to run
BXRX is a great $$$$$ opportunity.
9% short and tiny float new 52 week high == Boom tomorow
10.20 in AH
"We expect to make ANJESO available to physicians and patients in late April or early May 2020.”
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
404
|
Created
|
11/26/19
|
Type
|
Free
|
Moderators |
March 26, 2020 | 17.57M |
CHURCHILL WINSTON J | Director | Mar 26 | Buy | 2.28 | 6,500 | 14,820 | 6,500 | Mar 30 08:00 PM |
CHURCHILL WINSTON J | Director | Mar 26 | Buy | 2.44 | 25,000 | 61,000 | 52,782 | Mar 30 08:00 PM |
Weisman Wayne | Director | Mar 26 | Buy | 2.29 | 10,000 | 22,900 | 40,582 | Mar 27 03:53 PM |
ALTOMARI ALFRED | Director | Mar 26 | Buy | 2.34 | 5,000 | 11,700 | 33,382 | Mar 27 03:51 PM |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |